| 李阳安,徐 丽,汪 翼,何 诚,胡可慧.抗HP治疗对急性冠脉综合征合并HP感染患者血清炎性标记物及再发心肌缺血事件的影响[J].,2020,(10):1909-1912 |
| 抗HP治疗对急性冠脉综合征合并HP感染患者血清炎性标记物及再发心肌缺血事件的影响 |
| Effects of Anti-HP Therapy on Serum Inflammatory Markers and Recurrent Myocardial Ischemia in Patients with Acute Coronary Syndrome Combined with HP Infection |
| 投稿时间：2019-12-03 修订日期：2019-12-26 |
| DOI：10.13241/j.cnki.pmb.2020.10.025 |
| 中文关键词: 急性冠脉综合征 幽门螺杆菌 感染 炎性标记物 心肌缺血事件 |
| 英文关键词: Acute coronary syndrome Helicobacter pylori Infection Inflammatory markers Myocardial ischemic events |
| 基金项目:四川省卫生健康委员会科研项目（16PJ531）；四川省基层卫生事业发展研究中心资助项目（SWFZ18-Y-31） |
|
| 摘要点击次数: 793 |
| 全文下载次数: 434 |
| 中文摘要: |
| 摘要 目的：探讨抗幽门螺杆菌（HP）治疗对急性冠脉综合征（ACS）合并HP感染患者炎性标记物及再发心肌缺血事件的影响。方法：选取2016年10月到2018年10月期间我院收治的ACS患者90例，随机分为对照组（n=45，常规治疗）和观察组（n=45，常规治疗+抗HP治疗）。观察两组患者的临床疗效，比较HP根除率、血清炎性标记物[C反应蛋白（CRP）、白细胞介素-6（IL-6）、可溶性细胞间粘附分子-1（sICAM-1）]水平，记录再发心肌缺血事件和不良反应发生情况。结果：观察组的总有效率和HP根除率均高于对照组（P<0.05）。两组患者经治疗后血清CRP、IL-6、sICAM-1水平均较治疗前有所改善（P<0.05），且观察组的改善效果优于对照组（P<0.05）。观察组患者再发心肌缺血事件的总发生率低于对照组（P<0.05）。两组患者的不良反应发生率比较无明显差异（P>0.05）。结论：ACS合并HP感染患者采取抗HP治疗可更好地缓解患者体内的炎症反应，降低再发心肌缺血事件发生率的同时还不会增加不良反应发生风险。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of anti-Helicobacter pylori(HP) therapy on inflammatory markers and recurrent myocardial ischemia in patients with acute coronary syndrome (ACS) combined with HP infection. Methods: 90 patients with ACS who were treated in our hospital from October 2016 to October 2018 were selected, which were randomly divided into the control group (n=45, conventional therapy) and the observation group(n=45, conventional therapy combined anti-HP therapy). The clinical effect of the two groups was observed, HP eradication rate, serum inflammatory markers levels [C reactive protein(CRP), interleukin-6(IL-6), soluble intercellular adhesion molecule-1 (sICAM-1)] were compared between the two groups, the incidence of myocardial ischemia and adverse reactions were recorded. Results: The total effective rate and HP eradication rate of the observation group was higher than that of the control group(P<0.05). The levels of serum CRP, IL-6 and sICAM-1 the two groups were improved after treatment(P<0.05), and the improvement effect of the observation group is better than that of the control group(P<0.05). The total incidence of recurrent myocardial ischemic events in the observation group was lower than that in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Anti-HP therapy for patients with ACS and HP infection can better alleviate the inflammatory reaction in the body, reduce the incidence of recurrent myocardial ischemia events without increasing the risk of adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
